PEDIATRICS Vol. 104 No. 6 December 1999, pp. 1345-1350
Risk Factors for Chronic Lung Disease in the Surfactant Era: A North Carolina Population-based Study of Very Low Birth Weight Infants
Received Mar 10, 1999; accepted Jul 27, 1999.
,
, and
From the Departments of * Pediatrics and Maternal and Child
Health, University of North Carolina at Chapel Hill, Chapel Hill, North
Carolina; the § Department of Pediatrics, Wake Area Health Education
Center, Raleigh, North Carolina; and Wake Forest University School
of Medicine, Raleigh North Carolina.
Objective. To identify risk factors for chronic lung disease (CLD) in a population-based cohort of very low birth weight infants, born in an era of surfactant usage. We specifically investigated the effects of antenatal steroids, nosocomial infection, patent ductus arteriosus (PDA), fluid management, and ventilator support strategies.
Methods. Data were prospectively collected on 1244 infants born in North Carolina in 1994 with birth weights 500 to 1500 g, and treated at 1 of the 13 intensive care nurseries across the state. The outcome of interest was CLD, defined as dependency on supplemental oxygen at 36 weeks' postmenstrual age. Multivariate odds ratios (OR) and 95% confidence intervals (CI) were estimated with logistic regression models.
Results. Among 865 survivors to 36 weeks' postmenstrual age, 224 (26%) had CLD. Nosocomial infection (OR: 2.0; 95% CI: 1.4-3.3), fluid intake on day 2 (OR: 1.06 per 10 mL increase; 95% CI: 1.01-1.11), and the need for ventilation at 48 hours of life (OR: 2.2; 95% CI: 1.3-3.7) were associated with an increased risk of CLD. Among infants ventilated at 48 hours, nosocomial infection (OR: 1.64; 95% CI: 1.02-2.62) and PDA (OR: 1.9; 95% CI: 1.2-3.1) were associated with an increased risk. No association was found with antenatal steroid receipt or increased levels of ventilator support.
Conclusion. This analysis suggests that with widespread use of surfactant, nosocomial infection, PDA, and water balance persist as risk factors for CLD. Key words: chronic lung disease, bronchopulmonary dysplasia, prematurity, low birth weight, patent ductus arteriosus, betamethasone, infection, ventilation, neonatal factors.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Laughon, M. T. O'Shea, E. N. Allred, C. Bose, K. Kuban, L. J. Van Marter, R. A. Ehrenkranz, A. Leviton, and for the ELGAN Study Investigators Chronic Lung Disease and Developmental Delay at 2 Years of Age in Children Born Before 28 Weeks' Gestation Pediatrics, August 1, 2009; 124(2): 637 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Richards, A. Johnson, G. Fox, and M. Campbell A Second Course of Ibuprofen Is Effective in the Closure of a Clinically Significant PDA in ELBW Infants Pediatrics, August 1, 2009; 124(2): e287 - e293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D G Sweet and H L Halliday The use of surfactants in 2009 Arch. Dis. Child. Ed. Pract., June 1, 2009; 94(3): 78 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. T. Robertson, T. M. Howarth, D. L. R. Bork, and I. A. Dinu Permanent Bilateral Sensory and Neural Hearing Loss of Children After Neonatal Intensive Care Because of Extreme Prematurity: A Thirty-Year Study Pediatrics, May 1, 2009; 123(5): e797 - e807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laughon, E. N. Allred, C. Bose, T. M. O'Shea, L. J. Van Marter, R. A. Ehrenkranz, A. Leviton, and for the ELGAN Study Investigators Patterns of Respiratory Disease During the First 2 Postnatal Weeks in Extremely Premature Infants Pediatrics, April 1, 2009; 123(4): 1124 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Noori, M. McCoy, P. Friedlich, B. Bright, V. Gottipati, I. Seri, and K. Sekar Failure of Ductus Arteriosus Closure Is Associated With Increased Mortality in Preterm Infants Pediatrics, January 1, 2009; 123(1): e138 - e144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. McCurnin, S. Seidner, L.-Y. Chang, N. Waleh, M. Ikegami, J. Petershack, B. Yoder, L. Giavedoni, K. H. Albertine, M. J. Dahl, et al. Ibuprofen-Induced Patent Ductus Arteriosus Closure: Physiologic, Histologic, and Biochemical Effects on the Premature Lung Pediatrics, May 1, 2008; 121(5): 945 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Bose and M. M Laughon Patent ductus arteriosus: lack of evidence for common treatments Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2007; 92(6): F498 - F502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Chorne, C. Leonard, R. Piecuch, and R. I. Clyman Patent Ductus Arteriosus and Its Treatment as Risk Factors for Neonatal and Neurodevelopmental Morbidity Pediatrics, June 1, 2007; 119(6): 1165 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. McCurnin, B. A. Yoder, J. Coalson, P. Grubb, J. Kerecman, J. Kupferschmid, C. Breuer, T. Siler-Khodr, P. W. Shaul, and R. Clyman Effect of Ductus Ligation on Cardiopulmonary Function in Premature Baboons Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1569 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Cunha, F. Mezzacappa-Filho, and J. D. Ribeiro Risk Factors for Bronchopulmonary Dysplasia in very Low Birth Weight Newborns Treated with Mechanical Ventilation in the First Week of Life J Trop Pediatr, December 1, 2005; 51(6): 334 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Ehrenkranz, M. C. Walsh, B. R. Vohr, A. H. Jobe, L. L. Wright, A. A. Fanaroff, L. A. Wrage, K. Poole, and for the National Institutes of Child Health and Hu Validation of the National Institutes of Health Consensus Definition of Bronchopulmonary Dysplasia Pediatrics, December 1, 2005; 116(6): 1353 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Keller and R. I. Clyman Persistent Doppler Flow Predicts Lack of Response to Multiple Courses of Indomethacin in Premature Infants With Recurrent Patent Ductus Arteriosus Pediatrics, September 1, 2003; 112(3): 583 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Sharek, R. Baker, F. Litman, J. Kaempf, K. Burch, E. Schwarz, S. Sun, and N. R. Payne Evaluation and Development of Potentially Better Practices to Prevent Chronic Lung Disease and Reduce Lung Injury in Neonates Pediatrics, April 1, 2003; 111(4): e426 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Lal, B. N. Manktelow, E. S. Draper, and D. J. Field Chronic Lung Disease of Prematurity and Intrauterine Growth Retardation: A Population-Based Study Pediatrics, March 1, 2003; 111(3): 483 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Avent, D. Coile, and L. Mathai Neonatal Chronic Lung Disease Journal of Pharmacy Practice, June 1, 2001; 14(3): 181 - 206. [Abstract] [PDF]
|
|
|
|
|
|
A R B. Russell, A J B Emmerson, N Wilkinson, T Chant, D G Sweet, H L Halliday, B Holland, and E G Davies A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2001; 84(3): 172F - 176. [Abstract] [Full Text]
|
|
